Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > BMS to buy Turning Point Therapeutics for 4.1B$US

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Jun 03, 2022 9:32am

198 Views

Post# 34729242

RE:RE:RE:BMS to buy Turning Point Therapeutics for 4.1B$US

Thadeush... It's never the share price $ that you have to focus on as companies all have different shares outstanding.

You have to focus on the valuation (4.1B$US in this dxamol). Then, you divide it by the number of shares (fully diluted) of TLT to assess what would have been our equivalent.

As already documented many times, it always come back to a range of 2-10G$US for an oncology drug that is seen as a FDA approval. This was just another dxample.

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December